Extension Study for the Port Delivery System With Ranibizumab (Portal)
Status:
Recruiting
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the long-term safety and tolerability of the Port Delivery System
with ranibizumab (PDS) 100 mg/mL with refill-exchanges administered every 24 weeks (Q24W) or
every 36 weeks (Q36W) for approximately 144 weeks in participants with neovascular
age-related macular degeneration who have completed either Phase II Study GX28228 (Ladder),
Phase III Study GR40548 (Archway) or Phase IIIb Study WR42221 (Velodrome).